Repurposing of Antiviral Drugs for COVID-19 and Impact of Repurposed Drugs on the Nervous System

Overview

Journal Microb Pathog

Specialties Infectious Diseases
Microbiology

Date 2022 Jun 2

PMID 35654381

Authors

Madhura Punekar

Manas Kshirsagar

Chaitanya Tellapragada

Kanchankumar Patil

Affiliations

Soon will be listed here.

Abstract

The recent pandemic, Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has devastated humanity and is continuing to threaten us. Due to the high transmissibility of this pathogen, researchers are still trying to cope with the treatment and prevention of this disease. Few of them were successful in finding cure for COVID-19 by including repurposed drugs in the treatment. In such pandemic situations, when it is nearly impossible to design and implement a new drug target, previously designed antiviral drugs could help against novel viruses, referred to as drug repurposing/redirecting/repositioning or re-profiling. This review describes the current landscape of the repurposing of antiviral drugs for COVID-19 and the impact of these drugs on our nervous system. In some cases, specific antiviral therapy has been notably associated with neurological toxicity, characterized by peripheral neuropathy, neurocognitive and neuropsychiatric effects within the central nervous system (CNS).

Citing Articles

Bovine Serum Albumin Nanoparticle-Mediated Delivery of Ribavirin and Mycophenolic Acid for Enhanced Antiviral Therapeutics.

Castaneda Catana M, Rivas Marquina A, Dodes Traian M, Carlucci M, Damonte E, Perez O Viruses. 2025; 17(2).

PMID: 40006893 PMC: 11860702. DOI: 10.3390/v17020138.

Adverse drug reactions associated with COVID-19 management.

Chavda V, Dodiya P, Apostolopoulos V Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7353-7376.

PMID: 38743117 DOI: 10.1007/s00210-024-03137-0.

Potential Inhibitors of Lumpy Skin Disease's Viral Protein (DNA Polymerase): A Combination of Bioinformatics Approaches.

Zia S, Sumon M, Ashik M, Basar A, Lim S, Oh Y Animals (Basel). 2024; 14(9).

PMID: 38731287 PMC: 11083254. DOI: 10.3390/ani14091283.

Antivirals for Broader Coverage against Human Coronaviruses.

Outteridge M, Nunn C, Devine K, Patel B, McLean G Viruses. 2024; 16(1).

PMID: 38275966 PMC: 10820748. DOI: 10.3390/v16010156.

Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain.

Hernandez-Parra H, Reyes-Hernandez O, Figueroa-Gonzalez G, Carmen M, Gonzalez-Torres M, Pena-Corona S Front Cell Neurosci. 2023; 17:1125109.

PMID: 36998270 PMC: 10043238. DOI: 10.3389/fncel.2023.1125109.

References

Kamel W, Kamel M, Alhasawi A, Elmasry S, AlHamdan F, Al-Hashel J . Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson's Disease or Multiple Sclerosis. Front Neurol. 2021; 12:704186. PMC: 8529185. DOI: 10.3389/fneur.2021.704186. View

Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H . The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020; 6:28. PMC: 7195821. DOI: 10.1038/s41421-020-0169-8. View

Dunn C, Goa K . Zanamivir: a review of its use in influenza. Drugs. 1999; 58(4):761-84. DOI: 10.2165/00003495-199958040-00016. View

Lagging M, Wejstal R, Duberg A, Aleman S, Weiland O, Westin J . Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infect Dis (Lond). 2018; 50(8):569-583. DOI: 10.1080/23744235.2018.1445281. View

Bishara D, Kalafatis C, Taylor D . Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol. 2020; 10:2045125320935306. PMC: 7309390. DOI: 10.1177/2045125320935306. View

Nakamura S, Miyazaki T, Izumikawa K, Kakeya H, Saisho Y, Yanagihara K . Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study. Open Forum Infect Dis. 2017; 4(3):ofx129. PMC: 5534217. DOI: 10.1093/ofid/ofx129. View

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X . Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013; 57(4):1743-55. PMC: 3623363. DOI: 10.1128/AAC.02282-12. View

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z . Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020; 93(1):481-490. PMC: 7361300. DOI: 10.1002/jmv.26256. View

10.

Painter G, Natchus M, Cohen O, Holman W, Painter W . Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021; 50:17-22. PMC: 8277160. DOI: 10.1016/j.coviro.2021.06.003. View

11.

Leneva I, Kartashova N, Poromov A, Gracheva A, Korchevaya E, Glubokova E . Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses. 2021; 13(8). PMC: 8402645. DOI: 10.3390/v13081665. View

12.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

13.

Blaising J, Polyak S, Pecheur E . Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; 107:84-94. PMC: 7113885. DOI: 10.1016/j.antiviral.2014.04.006. View

14.

Neupane K, Ahmed Z, Pervez H, Ashraf R, Majeed A . Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts. Cureus. 2020; 12(6):e8845. PMC: 7386097. DOI: 10.7759/cureus.8845. View

15.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

16.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

17.

Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K . Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem. 2020; 104:104257. PMC: 7463036. DOI: 10.1016/j.bioorg.2020.104257. View

18.

Vankadari N . Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020; 56(2):105998. PMC: 7187825. DOI: 10.1016/j.ijantimicag.2020.105998. View

19.

Hulseberg C, Feneant L, Szymanska-de Wijs K, Kessler N, Nelson E, Shoemaker C . Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol. 2019; 93(8). PMC: 6450122. DOI: 10.1128/JVI.02185-18. View

20.

Elalfy H, Besheer T, El-Mesery A, El-Gilany A, Soliman M, Alhawarey A . Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021; 93(5):3176-3183. PMC: 8014583. DOI: 10.1002/jmv.26880. View